PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

The combination of cisplatin and topotecan as a second-line treatment for patients with advanced/recurrent uterine cervix cancer.

Abstract We retrospectively reviewed outcomes of treatments with cisplatin and topotecan in patients with previously-treated uterine cervix cancer.We analyzed the medical records of patients with advanced (stage IVB) or recurrent or persistent squamous or non-squamous cell carcinoma of the cervix, who were treated with cisplatin and topotecan as a second-line chemotherapy between January 2000 and December 2015. The patients were treated with a combination of cisplatin (50 mg/m for 1 day) and topotecan (0.75 mg/m for 3 days) once every 3 weeks. Treatment response, progression-free survival (PFS), and overall survival (OS) were analyzed in all patients and between responder and non-responder groups (responders showed at least a partial response to prior systemic chemotherapy).Thirty-nine patients with a median age of 47 years (range, 32-73 years) were treated with cisplatin and topotecan. The median PFS was 4.6 months (95% confidence interval [CI], 1.2-7.9 months) and the median OS was 14.1 months (95% CI, 10.0-18.2 months). The overall response rate (ORR) was 30.8%, and the disease control rate was 56.4%. The ORR was significantly better in the responder group compared with the non-responder group (50.0% vs 10.5%; P = .008). All patients reported some grade of hematological toxicity. The most frequently encountered toxicity was anemia, with a rate of 59.7% for any grade and 13.2% for grade 3 or 4.The combination of cisplatin and topotecan was effective as second-line chemotherapy in patients with advanced/recurrent uterine cervix cancer.
PMID
Related Publications

Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer.

Feasibility study on combination chemotherapy using nogitecan hydrochloride (topotecan) and cisplatin for patients with metastatic, persistent, or recurrent uterine cervical cancer.

A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.

Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.

Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29620661
OWN - NLM
STAT- MEDLINE
DCOM- 20180416
LR  - 20180416
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 14
DP  - 2018 Apr
TI  - The combination of cisplatin and topotecan as a second-line treatment for
      patients with advanced/recurrent uterine cervix cancer.
PG  - e0340
LID - 10.1097/MD.0000000000010340 [doi]
AB  - We retrospectively reviewed outcomes of treatments with cisplatin and topotecan
      in patients with previously-treated uterine cervix cancer.We analyzed the medical
      records of patients with advanced (stage IVB) or recurrent or persistent squamous
      or non-squamous cell carcinoma of the cervix, who were treated with cisplatin and
      topotecan as a second-line chemotherapy between January 2000 and December 2015.
      The patients were treated with a combination of cisplatin (50 mg/m for 1 day) and
      topotecan (0.75 mg/m for 3 days) once every 3 weeks. Treatment response,
      progression-free survival (PFS), and overall survival (OS) were analyzed in all
      patients and between responder and non-responder groups (responders showed at
      least a partial response to prior systemic chemotherapy).Thirty-nine patients
      with a median age of 47 years (range, 32-73 years) were treated with cisplatin
      and topotecan. The median PFS was 4.6 months (95% confidence interval [CI],
      1.2-7.9 months) and the median OS was 14.1 months (95% CI, 10.0-18.2 months). The
      overall response rate (ORR) was 30.8%, and the disease control rate was 56.4%.
      The ORR was significantly better in the responder group compared with the
      non-responder group (50.0% vs 10.5%; P = .008). All patients reported some grade 
      of hematological toxicity. The most frequently encountered toxicity was anemia,
      with a rate of 59.7% for any grade and 13.2% for grade 3 or 4.The combination of 
      cisplatin and topotecan was effective as second-line chemotherapy in patients
      with advanced/recurrent uterine cervix cancer.
FAU - Moon, Ji Young
AU  - Moon JY
AD  - Department of Internal Medicine, Cheongju Saint Mary's Hospital, Cheongju.
FAU - Song, Ik-Chan
AU  - Song IC
AD  - Department of Internal Medicine.
FAU - Ko, Young Bok
AU  - Ko YB
AD  - Department of Obstetrics and Gynecology.
FAU - Lee, Hyo Jin
AU  - Lee HJ
AD  - Department of Internal Medicine.
AD  - Infection Control Convergence Research Center, Chungnam National University
      College of Medicine, Daejeon, South Korea.
LA  - eng
PT  - Evaluation Studies
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 7M7YKX2N15 (Topotecan)
RN  - Q20Q21Q62J (Cisplatin)
SB  - AIM
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
MH  - Cisplatin/*administration & dosage
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*drug therapy/pathology
MH  - Retrospective Studies
MH  - Topotecan/*administration & dosage
MH  - Treatment Outcome
MH  - Uterine Cervical Neoplasms/*drug therapy/pathology
EDAT- 2018/04/06 06:00
MHDA- 2018/04/17 06:00
CRDT- 2018/04/06 06:00
PHST- 2018/04/06 06:00 [entrez]
PHST- 2018/04/06 06:00 [pubmed]
PHST- 2018/04/17 06:00 [medline]
AID - 10.1097/MD.0000000000010340 [doi]
AID - 00005792-201804060-00039 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Apr;97(14):e0340. doi: 10.1097/MD.0000000000010340.